Influenza vaccine (inactivated)
Brand names: Quadrivalent flu vaccines, Fluad (adjuvanted), Flucelvax (cell-based), Fluzone HD
The inactivated influenza vaccine provides active immunisation against seasonal influenza and is given annually, principally by intramuscular injection, to people in at-risk and eligible groups under the national programme.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It contains inactivated influenza virus antigens, reformulated each season to match anticipated circulating strains, which stimulate strain-specific protective antibodies.
Prescribing in practice
- Annual revaccination is required because circulating strains and antibody levels change, and the inactivated vaccine cannot cause influenza infection.
- Defer in significant acute febrile illness, and review egg-allergy status as some inactivated products are egg-grown, choosing an appropriate product per current guidance.
- Administer intramuscularly into the deltoid in adults, separating from other injections as advised.
Monitoring
No laboratory monitoring is needed; the patient should be observed briefly for immediate hypersensitivity after vaccination.
Counselling the patient
- You need a flu vaccine every year to stay protected as the virus changes.
- The injected vaccine is inactivated and cannot give you flu; a sore arm or mild fever can occur.
- Tell the vaccinator about any serious egg allergy or previous vaccine reaction.
Evidence & guidelines
Annual inactivated influenza vaccination follows the eligible groups and product recommendations of the UK immunisation guidance (Green Book) and seasonal flu programme.
Reference: UK Green Book; JCVI; annual NHS flu letter; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- HE-MACS (History and ECG-Based Manchester ACS Risk Score) · ACS Risk Stratification
- Weight-Based Levothyroxine Dose Calculator · Thyroid
- C-Peptide to Glucose Ratio · Diabetes Classification
- Number Needed to Treat (NNT) / Number Needed to Harm (NNH) · Evidence-Based Medicine
- IMDC (Heng) Score for Metastatic RCC · Renal Cell Carcinoma
- International Prognostic Index (IPI) for DLBCL · Lymphoma
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023